Our recent study shows that the reduced MYRF phosphorylation inhibits MYRF’s binding to mutant huntingtin and increases the expression of myelin-associated genes [38], suggesting that MYRF phosphorylation inhibition could be a druggable target for treating white matter degeneration in HD. The gene discussed is MYRF; the disease is Huntington disease.